Protocol Review and Monitoring System

摘要-方案审查和监测系统 美国罗伯特·H. Lurie综合癌症中心 (LCC)福尔斯属于科学审查委员会（SRC）的职权范围，SRC是 包括LCC的研究监督计划。LCC的PRMS自2009年以来一直获得NCI的批准。 1998. SRC是一个多学科委员会，由核心成员组成，提供必要的 在临床肿瘤学研究的主要学科的专业知识，与来自LCC的代表的专业知识 定量数据科学核心（包括生物统计学），转化研究，行为和健康 科学和药学团体。SRC由A主持。B。Benson III，MD，并由A.拉德梅克， 博士和J. Sosman，医学博士（新的在这个补助期）。SRC的重点是审查癌症相关临床 试验的科学价值，优先次序和监测科学进展。SRC有权批准 符合中心科学价值和科学优先事项的方案，并终止不符合中心科学价值和科学优先事项的方案。 充分体现科学进步。在这一赠款周期中所作的改进包括： 为疾病团队提供方案优先级和监测，改善研究人员之间的沟通 监督委员会和临床试验办公室，以及SRC的扩大代表性 会员资格

ABSTRACT – PROTOCOL REVIEW AND MONITORING SYSTEM The Protocol Review and Monitoring System (PRMS) of the Robert H. Lurie Comprehensive Cancer Center (LCC) falls under the purview of the Scientific Review Committee (SRC), one of several committees that comprise LCC's research oversight program. The LCC's PRMS has received continuous NCI approval since 1998. The SRC is a multidisciplinary committee that consists of a core group of members providing the necessary expertise in the principal disciplines of clinical oncology research, with expertise of representatives from LCC's Quantitative Data Sciences Core (which includes biostatistics), Translational Research, Behavioral and Health Sciences, and Pharmacy groups. The SRC is chaired by A. B. Benson III, MD, and co-chaired by A. Rademaker, PhD, and J. Sosman, MD (new in this grant period). The focus of the SRC is the review of cancer relevant clinical trials for scientific merit, prioritization, and monitoring scientific progress. The SRC has the authority to approve protocols that meet the scientific merit and scientific priorities of the center and to terminate protocols that do not demonstrate sufficient scientific progress. Improvements made over this grant cycle include an enhanced role for Disease Teams in protocol prioritization and monitoring, improved communication among the research oversight committees and with the Clinical Trials Office, as well as broadened representation of SRC membership.